Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus

Journal of Pharmacology and Pharmacotherapeutics

Volumn 2, Issue 4, 2011, Pages 230-235

  Dave, Darshan J ^a  

^a PDU Medical College   (India)

Author keywords

Dipeptidyl peptidase 4; glycemic control; hypoglycemia; metformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ARTICLE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE EDEMA; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTOPENIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; WEIGHT GAIN;

EID: 84865496065     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.85934     Document Type: Article

References (34)

1. Kulasa K, Edelman S. Saxagliptin: The evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2010;5:23-37.
2. Edelman S V, Henry RR. Diagnosis and Management of Type 2 Diabetes. West Islip, NY: Professional Communications, Inc; 2007.
3. Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-14.
4. Rodbard H W, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:541-59.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
6. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones N P, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
7. Meinert CL, Knatterud GL, Prout TE, Klimt CR. The University Group Diabetes Program: A study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;(Suppl 1):789-830.
8. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones N P, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
9. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: A teleoanalysis. Diabetes Care 2007;30:2248-54.
10. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009;26:249-62.
11. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
12. Garber AJ. Incretin based therapies in the management of type 2 diabetes: Rationale and reality in a managed care setting. Am J Manag Care 2010;16:187-94.
13. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med 2009;76 Suppl 5:S12-9.
14. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: Rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80.
15. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009;51:85-6.
16. Wang A, Dorso C, Kopcho L, Marcindeviciene J, Kirby MS. Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements [abstract no. 2088-PO]. Diabetes 2008;57 Suppl 1:A576-7.
17. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
18. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43.
19. Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;37:1164-71.
20. Label and approval history of ONGLYZA (saxagliptin): Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory. [Last accessed on 2011 Jan 31].
21. Deacon C F, Holst JJ. Saxagliptin: A new deipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009;26:488-99.
22. th scientific session. Diabetol Metab Syndr 2010;2:69.
23. Label and approval history of KOMBIGLYZE XR (Combination of saxagliptin and metformin hydrochloride extended release tablets). Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory. [Last accessed on 2011 Jan 31].
24. Sharma MD. Role of saxagliptin as monotherapy or adjuct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag 2010;6:233-7.
25. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9.
26. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gausenilsson I. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Diabetes Obes Metab 2011;13:523-32.
27. Rosenstock J, Sankoh S, List J F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86.
28. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11.
29. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11:611-22.
30. Hollander P, Li J, Allen E, Chen R, CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-9.
31. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract 2009;63:1395-406.
32. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009;32:1649-55.
33. Gokes B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I, for the D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31.
34. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010;26:2355-63.